Lipotecan

DRUG4 trials

Sponsors

Taiwan Liposome Company

Conditions

Advanced Solid TumorsAdvanced/Metastasis Renal Cell CarcinomaHepatoCellular CarcinomaHepatocellular CarcinomaPortal Vein Tumor Thrombosis

Phase 1

Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

CompletedNCT00747474

Taiwan Liposome CompanyAdvanced Solid Tumors

Start: 2008-09-30End: 2011-12-31Updated: 2019-11-18

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

TerminatedNCT03035006

Taiwan Liposome CompanyHepatoCellular Carcinoma, Portal Vein Tumor Thrombosis

Start: 2017-04-14End: 2018-10-31Updated: 2018-11-06

Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

CompletedNCT01831973

Taiwan Liposome CompanyAdvanced/Metastasis Renal Cell Carcinoma

Start: 2012-11-30End: 2017-02-21Updated: 2018-06-26

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

TerminatedNCT02267213

Taiwan Liposome CompanyHepatocellular Carcinoma

Start: 2014-04-10End: 2015-07-09Updated: 2019-02-26